COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients

Trial Profile

COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Coversin (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COBALT
  • Sponsors Akari Therapeutics
  • Most Recent Events

    • 11 Oct 2017 According to a company media release, Akari plans to provide an update on all PNH patients currently enrolled at the American Society of Hematology Annual Meeting to be held December 9-12, 2017.
    • 11 Oct 2017 According to an Akari Therapeutics media release, the protocol was amended based on a revised dosing regimen which included changing the maintenance phase from a single dose of 30mg every 24 hours to a single dose of 45mg every 24 hours.
    • 11 Oct 2017 According to an Akari Therapeutics media release, 3 additional patients have been enrolled in this trial. The three newly enrolled patients on the revised dosing regimen have now completed approximately 8, 3 and 2 weeks, respectively.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top